Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-101 for unwanted submental fat
ACTRN12607000243415Phase 2Not yet recruiting
- Sponsor
- Kythera Biopharmaceuticals
- Start
- Aug 2007
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
01
Overview
Phase 2, randomised trial of ATX101 in submental fat (4 arms), sponsored by Kythera Biopharmaceuticals. Primary endpoints: Incidence, severity, and duration of all treatment-emergent adverse events, Incidence of study material-related adverse events and 3 more. Planned start Aug 2007; status: not yet recruiting.
02
Drugs
ATX101
03
Conditions
submental fat
Beyond the preview
Go deeper on ACTRN12607000243415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000243415.